SLV308 for Treatment of Patients With Early Parkinson's Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

468

Participants

Timeline

Start Date

June 30, 2006

Primary Completion Date

December 31, 2007

Study Completion Date

December 31, 2007

Conditions
Early Stage Parkinson's Disease
Interventions
DRUG

pardoprunox

fixed dose 6 mg

DRUG

Pardoprunox

fixed dose 12 mg

DRUG

Pardoprunox

12-42mg

DRUG

Placebo

Placebo

Trial Locations (128)

Unknown

Site 284, Huntsville

Site 274, Little Rock

Site 283, Fountain Valley

Site 277, La Jolla

Site 271, San Francisco

Site 279, Fort Lauderdale

Site 293, Gainsville

Site 282, Port Charlotte

Site 285, Sunrise

Site 273, Tampa

Site 290, Chicago

Site 280, Kansas City

Site 292, Bingham Farms

Site 275, Traverse City

Site 276, St Louis

Site 287, St Louis

Site 278, Las Vegas

Site 286, Rochester

Site 288, Ashville

Site 289, Charlotte

Site 294, Toledo

Site 281, Pittsburgh

Site 291, Warwick

Site 272, Houston

Site 201, Buenos Aires

Site 202, Buenos Aires

Site 203, Buenos Aires

Site 204, Buenos Aires

Site 206, Buenos Aires

Site 208, Capital Federal, CBA

Site 207, Ciudad de Buenos Aires

Site 205, Córdoba

Site 100, Brussels

Site 101, Genk

Site 102, Wilrijk

Site 107, Plovdiv

Site 103, Sofia

Site 104, Sofia

Site 105, Sofia

Site 106, Sofia

Site 268, Barrie

Site 260, Calgary

Site 264, Greenfield Park

Site 263, Markham

Site 261, Ottawa

Site 266, Ottawa

Site 262, Québec

Site 265, Québec

Site 269, Saskatoon

Site 267, Toronto

Site 213, Providencia

Site 211, San Miguel

Site 210, Santiago

Site 212, Valdivia

Site 221, Bogotá

Site 223, Bogotá

Site 224, Bogotá

Site 220, Medellín

Site 222, Santiago de Cali

Site 111, Rijeka

Site 112, Split

Site 110, Zagreb

Site 113, Zagreb

Site 114, Zagreb

Site 123, Kuopio

Site 122, Lappeenranta

Site 120, Oulun Yliopisto

Site 121, Tampere

Site 124, Turku

Site 196, Bangalore

Site 194, Hyderabaad

Site 193, Mumbai

Site 195, Mumbai

Site 199, New Delhi

Site 198, Thiruvananthapuram

Site 197, Visakhapatnam

Site 131, Haifa

Site 132, Petah Tikva

Site 133, Ramat Gan

Site 130, Tel Aviv

Site 232, Aguascalientes

Site 230, Guadalajara - Jalisco

Site 231, Monterrey N.L.

Site 233, Tlalpan

Site 191, Christchurch

Site 190, Wellington South

Site 244, Barrios Altos-Lima

Site 241, La Victoria-Lima

Site 240, Lima

Site 243, San Isidro-Lima

Site 242, Surco-Lima

Site 143, Brasov

Site 140, Bucharest

Site 141, Craiova

Site 142, Mures

Site 158, Kazan'

Site 150, Moscow

Site 151, Moscow

Site 154, Moscow

Site 156, Moscow

Site 152, Saint Petersburg

Site 157, Saint Petersburg

Site 159, Saint Petersburg

Site 155, Smolensk

Site 153, Yaroslav

Site 160, Belgrade

Site 161, Belgrade

Site 162, Belgrade

Site 163, Niš

Site 170, Bratislava

Site 171, Bratislava

Site 174, Levice

Site 173, Nitra

Site 172, Žilina

Site 250, Cape Town

Site 252, Cape Town

Site 251, Durban

Site 253, Gauteng

Site 254, Pretoria

Site 127, Gothenburg

Site 126, Norrköping

Site 125, Stockholm

Site 180, Kharkiv

Site 183, Kharkiv

Site 181, Kyiv

Site 182, Kyiv

Site 185, Lviv

Site 184, Vinnytsia

All Listed Sponsors
lead

Solvay Pharmaceuticals

INDUSTRY

NCT00269516 - SLV308 for Treatment of Patients With Early Parkinson's Disease | Biotech Hunter | Biotech Hunter